glp-1 news 2025 october 21 GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists The expanding landscape of GLP-1
Description
The telehealth partner uses your content during onboarding and follow ups
doi: 10.1016/j.ejphar.2012.11.057
Cell Metab (2019) 30(5):98796.e6
There aren't many head-to-head studies yet, but cross-study comparisons show that triple agonism may help people lose more weight
Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for the treatment of type 2 diabetes, have demonstrated promising cognitive benefits, potentially mediated through improved insulin signaling, neuronal survival, and reduced -amyloid (A) and tau burden
